GMP Inspections Still A Risky Process For OTC Firms – Attorney
This article was originally published in The Tan Sheet
Executive Summary
FDA's cGMP regulation revisions reflect the agency's increasing focus on compliance for OTC manufacturers, according to Scott Bass of the Washington, D.C. law firm Sidley, Austin, Brown & Wood
You may also be interested in...
OTC Manufacturers Less Likely To Face Inspection Under cGMP Pilot
Manufacturing facilities that produce OTC drugs exclusively may not be inspected as often as plants that make prescription drugs under FDA's risk-based prioritization plan for inspections
OTC Manufacturers Less Likely To Face Inspection Under cGMP Pilot
Manufacturing facilities that produce OTC drugs exclusively may not be inspected as often as plants that make prescription drugs under FDA's risk-based prioritization plan for inspections
OTC Manufacturers Less Likely To Face Inspection Under cGMP Pilot
Manufacturing facilities that produce OTC drugs exclusively may not be inspected as often as plants that make prescription drugs under FDA's risk-based prioritization plan for inspections